1-3 of 3
Stephane E Allard
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

A Phase 2 Open-Label Safety and Tolerability Study of Single Intravenous (IV) Escalating Doses of 90 Yttrium-Labeled Antiferritin Antibodies ( 90 Y-Antiferritin) in Patients with Relapsed or Refractory Hodgkin Lymphoma

Didier Decaudin, MD, Alain Pecking, MD, François Lokiec, PhD, Jean Kadouche, PhD, Stephane E. Allard, MD
Journal: Blood
Blood (2014) 124 (21): 5468.
https://doi.org/10.1182/blood.V124.21.5468.5468
Published: 2014
Journal Articles

Pharmacokinetics (PK) and Pharmacodynamics (PD) of a New Direct Thrombin Inhibitor (DPOC-4088) After Single Oral Doses of Two Prolonged Release Formulations in Healthy Male Subjects,

Luc M Van Bortel, Griet Van Lancker, Henri Vanden Bavière, Willem Hettema, Edwin Spaans, Sankar Ramakrishnan, Venkatesan Elumalai, Suryakumar Jayanthi, Stephane E Allard
Journal: Blood
Blood (2011) 118 (21): 3351.
https://doi.org/10.1182/blood.V118.21.3351.3351
Published: 2011
Journal Articles

Post-Consolidation Immunotherapy with Histamine Dihydrochloride and Interleukin-2 in AML: Assessment of Consistency and Robustness of Treatment Benefit for Patients in First Complete Remission.

Marc E Buyse, ScD, Pierre Squifflet, MSc, Jacob M Rowe, MD, John K Whisnant, MD, Dileep Bhagwat, PhD, MBA, Stephane E Allard, MD, Kristoffer Hellstrand, MD, PhD, Mats L Brune, MD
Journal: Blood
Blood (2008) 112 (11): 1948.
https://doi.org/10.1182/blood.V112.11.1948.1948
Published: 2008